Provention Bio Stock Price

-0.28 (-6.6%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 334,820
Bid Price 3.86
Ask Price 4.50
News -
Day High 4.25


52 Week Range


Day Low 3.96
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Provention Bio Inc PRVB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.28 -6.6% 3.96 20:00:00
Open Price Low Price High Price Close Price Prev Close
4.25 3.96 4.25 3.96 4.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,804 334,820 $ 4.07 $ 1,364,176 - 3.40 - 9.70
Last Trade Time Type Quantity Stock Price Currency
19:56:01 5 $ 3.96 USD


Draw Mode:

Provention Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 253.60M 64.04M 58.41M $ 1.40M $ - -1.81 -2.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 267.00k 10.50%

more financials information »

Provention Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PRVB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.894.503.814.15877,1890.071.8%
1 Month4.184.733.54164.03710,627-0.22-5.26%
3 Months7.197.313.54164.51579,856-3.23-44.92%
6 Months6.068.043.405.23799,486-2.10-34.65%
1 Year9.429.703.405.94790,713-5.46-57.96%
3 Years11.2820.053.409.81889,960-7.32-64.89%
5 Years8.0022.821.529.87741,825-4.04-50.5%

Provention Bio Description

Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-6527, PRV-300, and PRV-101.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.